Castle Biosciences (CSTL): Dimensional reports 1,474,089 shares (5.1%)
Dimensional Fund Advisors LP reported beneficial ownership of 1,474,089 shares of Castle Biosciences Inc common stock, representing 5.1% of the class.
Rhea-AI Filing Summary
Dimensional Fund Advisors LP reported beneficial ownership of 1,474,089 shares of Castle Biosciences Inc common stock, representing 5.1% of the class. The filing states these shares are owned by investment funds advised or sub‑advised by Dimensional and that Dimensional disclaims beneficial ownership while reporting sole voting power over 1,447,712 shares and sole dispositive power over 1,474,089.
The Schedule 13G indicates the position is held in the ordinary course of business and not to influence control of the issuer. The filing was signed by Dimensional's Global Chief Compliance Officer on 10/09/2025.
Positive
- Material disclosure of 1,474,089 shares ( 5.1% ) provides transparency to investors
- Clear certification that the position is held in the ordinary course of business and not to influence control
Negative
- Dimensional disclaims beneficial ownership while reporting voting/dispositive power, which may limit clarity on ultimate economic ownership
- Passive status (Schedule 13G) means no stated engagement with issuer governance despite a >5% stake
Insights
Dimensional holds a passive but material 5.1% stake via managed funds.
The position of 1,474,089 shares equals a modest, reportable stake that meets the >5% disclosure threshold and is reported on Schedule 13G, which typically signals a passive investment rather than an intent to change control.
This holding gives Dimensional sole voting power over 1,447,712 shares while it disclaims beneficial ownership because the securities are owned by the Funds it advises. Monitor any future amendments or Schedule 13D filings for changes in intent or increased ownership.
Filing reflects standard adviser reporting and compliance certification.
The form identifies Dimensional as an investment adviser and contains the certification that the shares are held in the ordinary course of business and not to influence issuer control. The signature by the Global Chief Compliance Officer completes the required attestation.
Regulatory items to watch include any shift from Schedule 13G to Schedule 13D or material changes in voting/dispositive power; the current filing documents the passive status as of 10/09/2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Dimensional Fund Advisors hold in Castle Biosciences (CSTL)?
Was this position reported as passive or active?
When was the Schedule 13G signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.